큐로셀

Business Overview

CurioCell is a South Korean biotech company specializing in cell and gene therapy, established in 2016 as the first firm to receive clinical trial approval for next-generation CAR-T therapies in Korea. It develops multiple pipelines, including CD19 CAR-T, blood cancer, and solid tumor CAR-T, and employs proprietary OVIS™ CAR-T technology that combines CAR-T with immune checkpoint inhibition to enhance efficacy. Its lead candidate, Limcato (Anbal-cel), achieved a 75.3% objective response rate in Phase II trials, outperforming existing FDA-approved CAR-T therapies. The company plans to build a commercial GMP production facility in Daejeon by mid-2025.